All Stories

  1. Fractional flow reserve derived from coronary CT angiography: Variation of repeated analyses
  2. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial
  3. Randomised comparison of manual compression and FemoSealª vascular closure device for closure after femoral artery access coronary angiography: the CLOSure dEvices Used in everyday Practice (CLOSE-UP) study
  4. Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial
  5. Mechanical chest compressions improve quality of CPR in out-of-hospital cardiac arrest
  6. Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups
  7. REPRODUCIBILITY OF INVASIVELY MEASURED AND NON-INVASIVELY COMPUTED FRACTIONAL FLOW RESERVE
  8. VERY LATE STENT THROMBOSIS AFTER REVASCULARIZATION WITH EVEROLIMUS- AND SIROLIMUS-ELUTING STENTS FROM THE SORT OUT IV TRIAL
  9. LONG-TERM CLINICAL OUTCOMES OF EVEROLIMUS-ELUTING STENTS VERSUS SIROLIMUS-ELUTING STENTS IN PATIENTS WITH CORONARY ARTERY DISEASE: SORT OUT IV 4-YEAR
  10. Diagnostic Performance of Noninvasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Suspected Coronary Artery Disease
  11. Similar five-year outcome with paclitaxel- and sirolimus-eluting coronary stents
  12. Long‐term outcome following percutaneous coronary intervention with drug‐eluting stents compared with bare‐metal stents in saphenous vein graft lesions: From Western Denmark heart registry
  13. Quantitative Point-of-Care Troponin T Measurement for Diagnosis and Prognosis in Patients With a Suspected Acute Myocardial Infarction
  14. Clinical Outcome After Crush Versus Culotte Stenting of Coronary Artery Bifurcation Lesions
  15. TCT-12 Short Versus Long-Term Clinical Outcomes In A Randomised Comparison Of Zotarolimus- and Sirolimus-Eluting Coronary Stents
  16. TCT-630 Vascular Response to Biolimus-eluting and Sirolimus-Eluting Stents in Patients with ST-segment Elevation Myocardial Infarction
  17. TCT-665 Co-registration of Optical Coherence Tomography and X-ray Angiography in Percutaneous Coronary Intervention. The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Fusion Study
  18. TCT-214 Five-year prognostic impact of distal embolization during primary percutaneous coronary intervention in ST elevation myocardial infarction patients treated with or without distal protection
  19. TCT-194 5-Year Outcome Of Zotarolimus-Eluting Versus Sirolimus-Eluting Coronary Stent Implantation In Patients With And Without Diabetes Mellitus
  20. TCT-598 Mechanisms of Incomplete Stent Apposition After Implantation of Drug-eluting Stents in patients with ST-segment Elevation Myocardial Infarction
  21. TCT-26 Randomized Comparison Of Final Kissing Balloon Dilatation Versus No Final Kissing Balloon Dilatation In Patients With Coronary Bifurcation Lesions Treated With Main Vessel Stenting. Three Year Clinical Outcome In The Nordic-Baltic Bifurcation St...
  22. Intimal hyperplasia and vascular remodeling after everolimus‐eluting and sirolimus‐eluting stent implantation in diabetic patients: The randomized diabetes and drug‐eluting stent (DiabeDES) IV intravascular ultrasound trial
  23. Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology
  24. Rationale and design of the HeartFlowNXT (HeartFlow analysis of coronary blood flow using CT angiography: NeXt sTeps) study
  25. Intravascular ultrasound assessed incomplete stent apposition and stent fracture in stent thrombosis after bare metal versus drug-eluting stent treatment the Nordic Intravascular Ultrasound Study (NIVUS)
  26. Three‐dimensional multidetector computed tomography versus conventional 2‐dimensional transesophageal echocardiography for annular sizing in transcatheter aortic valve replacement: Influence on postprocedural paravalvular aortic regurgitation
  27. Acquired peri-stent evaginations in a second generation durable polymer drug eluting stent
  28. Long-Term Results After Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions
  29. Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction
  30. Consensus from the 7th European Bifurcation Club meeting
  31. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Rationale and design of the randomized, double-blind Administration of Ticagrelor in ...
  32. VERY LATE STENT THROMBOSIS AFTER REVASCULARIZATION WITH EVEROLIMUS AND SIROLIMUS–ELUTING STENTS: FROM THE SORT OUT IV TRIAL
  33. HYBRID CORONARY REVASCULARIZATION COMBINING OFF–PUMP LEFT INTERNAL MAMMARY GRAFTING AND PCI
  34. PREVENTION OF CONTRAST–INDUCED NEPHROPATHY IN PATIENTS WITH RENAL INSUFFICIENCY WITH STEMI
  35. LONG–TERM OUTCOME AFTER REVASCULARIZATION WITH EVEROLIMUS– AND SIROLIMUS–ELUTING STENTS IN PATIENTS WITH RENAL INSUFFICIENCY: FROM THE SORT OUT IV TRIAL
  36. Outcomes after primary percutaneous coronary intervention in octogenarians and nonagenarians with ST‐segment elevation myocardial infarction: From the Western Denmark heart registry
  37. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial
  38. CRT-58 Hybrid Coronary Revascularization Combining Off-pump Left Internal Mammary Grafting And Percutaneous Coronary Intervention
  39. Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the SORT OUT IV Trial)
  40. Sex- and age-related differences in clinical outcome after primary percutaneous coronary intervention
  41. Timely and optimal treatment of patients with STEMI
  42. Incidence of definite stent thrombosis or in‐stent restenosis after drug‐eluting stent implantation for treatment of coronary in‐stent restenosis: From Western Denmark heart registry
  43. Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry
  44. TCT-297 Stent edge dissections detected by Optical Coherence Tomography, incidence, predictors and 12-month outcome
  45. TCT-283 Intimal Hyperplasia and Vascular Remodeling after Everolimus-eluting and Sirolimus-eluting Stent Implantation in Diabetic Patients. The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound Trial
  46. TCT-355 Coronary Stents In Patients With Diabetes Mellitus: The Diabetes And Drug-Eluting Stent (DiabeDES IV) Randomized Angiography Trial
  47. TCT-347 Clinical Outcome Of Biolimus-Eluting Versus Sirolimus-Eluting Coronary Stent Implantation In Patients With And Without Diabetes Mellitus: A SORT OUT V Substudy
  48. TCT-55 Major Adverse Cardiac Events Associated With Discontinuation Of Clopidogrel Treatment Within The First Year After Coronary Stent Implantation In Western Denmark
  49. TCT-301 Feasibility and Results of Novel Side Branch Evaluation by Reconstructed 3-Dimensional Optical Coherence Tomography. Matched Analysis of Baseline and 12-month follow-up in Native, Jailed and Opened Side Branches
  50. 2-Year Patient-Related Versus Stent-Related Outcomes
  51. The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation
  52. Culprit only or multivessel percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction and multivessel disease
  53. 3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents
  54. Zotarolimus‐eluting vs. sirolimus‐eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy
  55. The Nordic Experience
  56. Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy)
  57. Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction
  58. DIMENSIONS OF SOCIOECONOMIC STATUS AND CLINICAL OUTCOME AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION
  59. TWO-YEAR PATIENT-RELATED VERSUS STENT-RELATED OUTCOMES FROM THE SORT OUT IV TRIAL
  60. DEFINITE AND PROBABLE STENT THROMBOSIS AFTER REVASCULARIZATION WITH EVEROLIMUS- AND SIROLIMUS-ELUTING STENTS. FROM THE SORT OUT IV TRIAL
  61. IMPACT OF LESION LENGTH ON OUTCOMES AFTER REVASCULARIZATION WITH EVEROLIMUS AND SIROLIMUS ELUTING STENTS. A SUBSTUDY OF THE SORT OUT IV TRIAL
  62. OUTCOMES AFTER REVASCULARIZATION WITH EVEROLIMUS AND SIROLIMUS ELUTING STENTS IN PATIENTS WITH SMALL AND LARGE CORONARY ARTERIES. A SUBSTUDY OF THE SORT OUT IV TRIAL
  63. Side branch fractional flow reserve measurements after main vessel stenting: a Nordic-Baltic Bifurcation Study III substudy
  64. Earlier reperfusion in patients with ST-elevation Myocardial infarction by use of helicopter
  65. Comparison of Outcomes of Patients ≥80 Years of Age Having Percutaneous Coronary Intervention According to Presentation (Stable vs Unstable Angina Pectoris/Non–ST-Segment Elevation Myocardial Infarction vs ST-Segment Elevation Myocardial Infarction)
  66. Outcome of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (a SORT OUT III Substudy)
  67. Health Care System Delay and Heart Failure in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Follow-up of Population-Based Medical Registry Data
  68. Use of three-dimensional optical coherence tomography to verify correct wire position in a jailed side branch after main vessel stent implantation
  69. Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial
  70. Prehospital Troponin T Testing in the Diagnosis and Triage of Patients With Suspected Acute Myocardial Infarction
  71. Nonsteroidal Antiinflammatory Drug Use and Cardiovascular Risks After Coronary Stent Implantation
  72. Long-term safety and efficacy of drug-eluting stents
  73. TROPONIN T TESTING IN THE PREHOSPITAL DIAGNOSIS AND TRIAGE OF PATIENTS WITH SUSPECTED HEART ATTACK
  74. Quality of cardiopulmonary resuscitation in out-of-hospital cardiac arrest is hampered by interruptions in chest compressions—A nationwide prospective feasibility study
  75. One or two stents for coronary bifurcation lesions?
  76. Zotarolimus-eluting versus sirolimus-eluting coronary stent implantation
  77. Sirolimus-eluting versus bare-metal stent implantation in patients with ostial lesions
  78. Quantitative coronary analysis in the Nordic Bifurcation studies
  79. Reply
  80. Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction
  81. Review of Registry and Randomised Comparisons of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents in Western Denmark
  82. Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With and Without Diabetes Mellitus in Western Denmark
  83. Consensus from the 5th European Bifurcation Club meeting
  84. Cardiac arrest in the catheterisation laboratory: A 5-year experience of using mechanical chest compressions to facilitate PCI during prolonged resuscitation efforts
  85. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry
  86. Increased Rate of Stent Thrombosis and Target Lesion Revascularization After Filter Protection in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
  87. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial
  88. LONG-TERM CLINICAL OUTCOME AFTER IMPLANTATION OF SIROLIMUS-ELUTING AND PACLITAXEL-ELUTING STENTS IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS - A PREDEFINED SORT OUT II SUBSTUDY
  89. CLINICAL PRESENTATION OF IN-STENT RESTENOSIS AND ANGIOGRAPHIC CONFIRMED STENT THROMBOSIS IN PATIENTS TREATED WITH BARE METAL OR DRUG-ELUTING STENTS. FROM WESTERN DENMARK HEART REGISTRY
  90. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial
  91. Rationale and Design of a Randomized Clinical Comparison of Everolimus-Eluting (Xience V/Promus) and Sirolimus-Eluting (Cypher Select+) Coronary Stents in Unselected Patients with Coronary Heart Disease
  92. Prevalence and Significance of Accelerated Idioventricular Rhythm in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
  93. Scintigraphic evaluation of routine filterwire distal protection in percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: a randomized controlled trial
  94. Outcome in high risk patients with unprotected left main coronary artery stenosis treated with percutaneous coronary intervention
  95. Percutaneous coronary intervention for bifurcation lesions: 2008 consensus document from the fourth meeting of the European Bifurcation Club
  96. Serial Intravascular Ultrasound Analysis of Peri-Stent Remodeling and Proximal and Distal Edge Effects After Sirolimus-Eluting or Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus
  97. Comparison of the Sirolimus-Eluting Versus Paclitaxel-Eluting Coronary Stent in Patients With Diabetes Mellitus: The Diabetes and Drug-Eluting Stent (DiabeDES) Randomized Angiography Trial††A list of participating centers and investigators appears in t...
  98. 2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents
  99. ST changes before and during primary percutaneous coronary intervention predict final infarct size in patients with ST elevation myocardial infarction
  100. Temporal Course of Pregnancy-Associated Plasma Protein-A in Angioplasty-Treated ST-Elevation Myocardial Infarction Patients and Potential Significance of Concomitant Heparin Administration
  101. Safety in simple versus complex stenting of coronary artery bifurcation lesions. The Nordic Bifurcation Study 14-month follow-up results
  102. Intravascular Ultrasound Assessment of Expansion of the Sirolimus-Eluting (Cypher Select) and Paclitaxel-Eluting (Taxus Express-2) Stent in Patients With Diabetes Mellitus
  103. Comparison of Stent Thrombosis, Myocardial Infarction, and Mortality Following Drug-Eluting Versus Bare-Metal Stent Coronary Intervention in Patients With Diabetes Mellitus
  104. Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions
  105. Randomized Comparison of Distal Protection Versus Conventional Treatment in Primary Percutaneous Coronary Intervention
  106. Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice
  107. Classification of coronary artery bifurcation lesions and treatments: Time for a consensus!
  108. Efficiency and safety of the sirolimus eluting stent in complex coronary artery lesions after cessation of dual antiplatelet therapy: fifteen months clinical outcome of the randomised Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTE...
  109. Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions
  110. Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent
  111. Does Postsystolic Motion or Shortening Predict Recovery of Myocardial Function After Primary Percutanous Coronary Intervention?
  112. Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: Subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT)
  113. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) Trial
  114. Prehospital evaluation in ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention
  115. When analyses are invalidated by erroneous assumptions
  116. Haemostatic Activity in Patients with Atrial Fibrillation Treated with Low-Molecular-Weight Heparin Before and After Electrical Cardioversion
  117. Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation?
  118. Cholesterol reduction following health screening in general practice
  119. Prospective evaluation of the quality of oral anticoagulation management in an outpatient clinic and in general practices
  120. Evaluation of a Simple Dosage Scheme for Transition from Phenprocoumon to Warfarin in Oral Anticoagulation
  121. Effect of Anticoagulant Therapy on the Hypercoagulable State in Patients Carrying the Factor V Arg506Gln Mutation
  122. The Arg506Gln Mutation (FV Leiden) Among a Cohort of 4188 Unselected Danish Newborns
  123. C-reactive protein in general practice - how commonly is it used and why?
  124. Research, technology assessment, and quality assurance
  125. Hallucinogenic mushroom use by Danish students: pattern of consumption